Panel discussions
Over the last few years, Europe has experienced a decline in oncology clinical trial activity, losing ground to the U.S., China, and Australia. Despite an overall increase in global oncology trials, site activation timelines have lengthened, and patient access to new therapies has slowed. This panel discussion will convene key stakeholders to explore strategies for strengthening Europe’s clinical trial ecosystem and reclaiming its leadership in global oncology research.
May 5, 17:30-18:15, Marriott 3+4+5
| Name | Position | Institution |
|---|---|---|
| Rute Marques | CEO | ROK Communications |
| Name | Position | Institution |
|---|---|---|
| Pilar de la Rocha Mur | Head of Clinical Operations, EMEA | BeiGene |
| Dr. Anna Maria Frustaci | ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy | |
| David Alsadius | Solid Tumor Franchise Lead | IQVIA |
BeiGene, which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them.
